Skip to Content

What type of drug is Emgality?

Medically reviewed by Last updated on Jun 5, 2019.

Official Answer


Emgality (galcanezumab-gnlm) is a calcitonin gene-related peptide (CGRP) antagonist used for the prevention of migraine, and for the treatment of cluster headache in adults.

When CGRP binds to its receptor, a cascade of events such as vasodilation and protein leakage begin that results in inflammation and pain associated with migraine.

Emgality from Eli Lilly is the third drug approved in this class of drugs, joining previously approved CGRP antagonists Ajovy (fremanezumab-vfrm) from Teva Pharmaceutical and Aimovig (erenumab-aooe) from Amgen.

How do calcitonin gene-related peptide (CGRP) antagonists work?

  • Emgality and Ajovy work similarly: they bind to the CGRP ligand and block its binding to the receptor to help prevent migraine pain.
  • Aimovig selectively binds to the CGRP receptor (not the ligand) to block CGRP activation, thereby preventing migraine pain.


Related Medical Questions

Drug Information

Related Support Groups